Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,765 across all filing types
Latest filing 2022-12-14 Capital/Financing Update
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Redemption
Capital/Financing Update Classification · 95% confidence The document is a short official communication from Torrent Pharmaceuticals Limited dated 14th December 2022. It informs about the partial redemption of Non-Convertible Debentures (NCDs) worth 142.86 crores out of a total of 1000 crores issued. The document references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content is an update on a financing activity (redemption of debt securities), not a full financial report or audit. The document length is only 1355 characters, indicating it is a brief announcement rather than a detailed report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-12-14 English
Partial Redemption of Non-Convertible Debentures
Capital/Financing Update Classification · 95% confidence The document is a short letter dated 14th December 2022 from Torrent Pharmaceuticals Limited addressed to stock exchanges (BSE and NSE). It announces the partial redemption of Non-Convertible Debentures (NCDs) worth 142.86 crores out of a total of 1000 crores issued. The letter references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content is an update on a financing activity (redemption of debt securities), not a full financial report or audit. The document length is only 1355 characters, indicating it is a brief announcement rather than a detailed report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-12-14 English
Press Release
Capital/Financing Update Classification · 85% confidence The document is a press release announcing a strategic co-marketing partnership between Torrent Pharmaceuticals Ltd and Boehringer Ingelheim India Private Limited. It provides details about the partnership, the products involved, market context, and statements from company directors. There are no financial statements, regulatory certifications, voting results, or detailed financial data. The document is an announcement of a business development rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The closest fitting category is Capital/Financing Update (CAP) since it relates to a strategic business partnership that could impact the company's market and capital position, although it is not a direct financing announcement. Given the nature of the announcement, CAP is the best classification with moderate to high confidence.
2022-12-14 English
Torrent Pharmaceuticals Ltd enters into co-marketing partnership with Boehringer Ingelheim India Private Limited to co- market its anti-diabetic drug and its fixed dose combinations in India
Regulatory Filings Classification · 95% confidence The document is a press release announcing a strategic co-marketing partnership between Torrent Pharmaceuticals Ltd and Boehringer Ingelheim India Private Limited. It provides details about the partnership, the products involved, market context, and company background. There are no financial statements, regulatory filings, voting results, or management discussions. The document is an announcement of a business partnership rather than a financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-12-14 English
Newspaper Advertisements
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the listing department of BSE Limited regarding a newspaper advertisement about the transfer of shares to the Investor Education and Protection Fund (IEPF). It includes copies of newspaper cuttings as enclosures. The content is an announcement related to share transfer compliance and does not contain financial data, management discussion, or report details. The document length is short (1534 characters), and it serves as a notification to the stock exchange rather than a report or detailed filing. This fits best under Regulatory Filings (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-12-08 English
Newspaper advertisement in respect of the transfer of shares to IEPF
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the BSE Limited listing department regarding a newspaper advertisement about the transfer of shares to the Investor Education and Protection Fund (IEPF). It includes copies of newspaper cuttings as enclosures. The content is an official communication about share transfer related to regulatory compliance, not a financial report, earnings release, or management discussion. The document length is short (1534 characters), and it is an announcement of an event rather than a detailed report. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-12-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.